243 related articles for article (PubMed ID: 9611102)
21. [The use of granisetron per os in radiotherapy-induced emesis].
Krengli M; Lazzari R; Manara M
Minerva Med; 1996 Dec; 87(12):605-8. PubMed ID: 9064597
[TBL] [Abstract][Full Text] [Related]
22. Granisetron: is there a dose-response effect on nausea and vomiting?
Minami M
Cancer Chemother Pharmacol; 2003 Aug; 52(2):89-98. PubMed ID: 12783208
[TBL] [Abstract][Full Text] [Related]
23. Granisetron in the prevention of vomiting induced by conditioning for stem cell transplantation: a prospective randomized study.
Okamoto S; Takahashi S; Tanosaki R; Sakamaki H; Onozawa Y; Oh H; Miyawaki S; Kimura Y; Toyama K; Ikeda Y; Asano S
Bone Marrow Transplant; 1996 May; 17(5):679-83. PubMed ID: 8733681
[TBL] [Abstract][Full Text] [Related]
24. Management of platinum-based chemotherapy-induced acute nausea and vomiting: is there a superior serotonin receptor antagonist?
Hamadani M; Chaudhary L; Awan FT; Khan JK; Kojouri K; Ozer H; Tfayli A
J Oncol Pharm Pract; 2007 Jun; 13(2):69-75. PubMed ID: 17873106
[TBL] [Abstract][Full Text] [Related]
25. [Granisetron (per os) compared with ondansetron (per os) in the prevention of nausea and vomiting induced by mildly emetogenic chemotherapies. Groupe de Recherches en Cancerologie du Nord].
Huc P; Block S; Carlier D; Darloy F; Bonneterre ME; Bleuse JP; Fournier C; Bonneterre J
Bull Cancer; 1998 Jun; 85(6):562-8. PubMed ID: 9752283
[TBL] [Abstract][Full Text] [Related]
26. Evidence for a 5-HT3 receptor involvement in the facilitation of peristalsis on mucosal application of 5-HT in the guinea pig isolated ileum.
Tuladhar BR; Kaisar M; Naylor RJ
Br J Pharmacol; 1997 Nov; 122(6):1174-8. PubMed ID: 9401783
[TBL] [Abstract][Full Text] [Related]
27. [An experimental study of the role of a blockade of serotonin 5-HT3 receptors and dopamine D2 receptors in the mechanism of the occurrence of early radiation vomiting in monkeys].
Martirosov KS; Grigor'ev IuG; Zorin VV; Andrianova IE
Radiats Biol Radioecol; 2000; 40(3):277-80. PubMed ID: 10907404
[TBL] [Abstract][Full Text] [Related]
28. Effects of granisetron, a selective 5-HT3 receptor antagonist, on ouabain-induced emesis in ferrets.
Endo T; Sugawara J; Nemoto M; Minami M; Blower PR
Res Commun Mol Pathol Pharmacol; 1998 Dec; 102(3):227-39. PubMed ID: 10342910
[TBL] [Abstract][Full Text] [Related]
29. The efficacy of 5-HT3 receptor antagonists for the prevention of postoperative nausea and vomiting after craniotomy: a meta-analysis.
Neufeld SM; Newburn-Cook CV
J Neurosurg Anesthesiol; 2007 Jan; 19(1):10-7. PubMed ID: 17198095
[TBL] [Abstract][Full Text] [Related]
30. Palonosetron: a unique 5-HT3 receptor antagonist indicated for the prevention of acute and delayed chemotherapy-induced nausea and vomiting.
Rubenstein EB
Clin Adv Hematol Oncol; 2004 May; 2(5):284-9. PubMed ID: 16163194
[TBL] [Abstract][Full Text] [Related]
31. Pharmacological and anti-emetic properties of ondansetron.
Tyers MB; Bunce KT; Humphrey PP
Eur J Cancer Clin Oncol; 1989; 25 Suppl 1():S15-9. PubMed ID: 2533894
[TBL] [Abstract][Full Text] [Related]
32. Interaction of the antiemetics ondansetron and granisetron with the cytotoxicity induced by irradiation, epirubicin, bleomycin, estramustine, and cisplatin in vitro.
Behnam Motlagh P; Henriksson R; Grankvist K
Acta Oncol; 1995; 34(6):871-5. PubMed ID: 7576757
[TBL] [Abstract][Full Text] [Related]
33. Selectivity of 5-HT3 receptor antagonists and anti-emetic mechanisms of action.
Freeman AJ; Cunningham KT; Tyers MB
Anticancer Drugs; 1992 Apr; 3(2):79-85. PubMed ID: 1525396
[TBL] [Abstract][Full Text] [Related]
34. [An outline of 5-HT3 receptor antagonists (1)--In pharmacological actions].
Tsukagoshi S; Ohta J; Taguchi T
Gan To Kagaku Ryoho; 1993 Nov; 20(14):2108-14. PubMed ID: 8239673
[TBL] [Abstract][Full Text] [Related]
35. 5-HT3 receptor antagonists for prevention of late acute-onset emesis.
Constenla M
Ann Pharmacother; 2004 Oct; 38(10):1683-91. PubMed ID: 15316106
[TBL] [Abstract][Full Text] [Related]
36. The effects of ondansetron and granisetron on electrocardiography in children receiving chemotherapy for acute leukemia.
Buyukavci M; Olgun H; Ceviz N
Am J Clin Oncol; 2005 Apr; 28(2):201-4. PubMed ID: 15803017
[TBL] [Abstract][Full Text] [Related]
37. Palonosetron exhibits unique molecular interactions with the 5-HT3 receptor.
Rojas C; Stathis M; Thomas AG; Massuda EB; Alt J; Zhang J; Rubenstein E; Sebastiani S; Cantoreggi S; Snyder SH; Slusher B
Anesth Analg; 2008 Aug; 107(2):469-78. PubMed ID: 18633025
[TBL] [Abstract][Full Text] [Related]
38. 5-hydroxytryptamine-3 receptor antagonist with or without short-course dexamethasone in the prophylaxis of radiation induced emesis: a placebo-controlled randomized trial of the National Cancer Institute of Canada Clinical Trials Group (SC19).
; Wong RK; Paul N; Ding K; Whitehead M; Brundage M; Fyles A; Wilke D; Nabid A; Fortin A; Wilson D; McKenzie M; Ackerman I; Souhami L; Chabot P; Pater J
J Clin Oncol; 2006 Jul; 24(21):3458-64. PubMed ID: 16849762
[TBL] [Abstract][Full Text] [Related]
39. Diverging effects of 5-HT3 receptor antagonists ondansetron and granisetron on estramustine-inhibited cellular potassium transport.
Behnam-Motlagh P; Sandström PE; Henriksson R; Grankvist K
Pharmacol Toxicol; 2001 May; 88(5):244-9. PubMed ID: 11393584
[TBL] [Abstract][Full Text] [Related]
40. 5-hydroxytryptamine type-3 receptor antagonists for chemotherapy-induced and radiotherapy-induced nausea and emesis: can we safely reduce the dose of administered agents?
Aapro M; Blower P
Cancer; 2005 Jul; 104(1):1-18. PubMed ID: 15929119
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
